Allarity Therapeutics Stock Probability of Future Stock Price Finishing Over 448.2
| ALLR Stock | USD 1.27 0.01 0.79% |
Allarity |
Allarity Therapeutics Target Price Odds to finish over 448.2
The tendency of Allarity Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 448.20 or more in 90 days |
| 1.27 | 90 days | 448.20 | close to zero percent |
Based on a normal probability distribution, the odds of Allarity Therapeutics to move over $ 448.20 or more in 90 days from now is close to zero percent (This Allarity Therapeutics probability density function shows the probability of Allarity Stock to fall within a particular range of prices over 90 days) . Probability of Allarity Therapeutics price to stay between its current price of $ 1.27 and $ 448.20 at the end of the 90-day period is about 80.04 .
Given the investment horizon of 90 days Allarity Therapeutics has a beta of 0.88. This suggests Allarity Therapeutics market returns are sensible to returns on the market. As the market goes up or down, Allarity Therapeutics is expected to follow. Additionally Allarity Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Allarity Therapeutics Price Density |
| Price |
Predictive Modules for Allarity Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Allarity Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Allarity Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Allarity Therapeutics is not an exception. The market had few large corrections towards the Allarity Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Allarity Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Allarity Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.88 | |
β | Beta against Dow Jones | 0.88 | |
σ | Overall volatility | 1.40 | |
Ir | Information ratio | -0.25 |
Allarity Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Allarity Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Allarity Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Allarity Therapeutics generated a negative expected return over the last 90 days | |
| Allarity Therapeutics has high historical volatility and very poor performance | |
| Allarity Therapeutics may become a speculative penny stock | |
| Allarity Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Allarity Therapeutics currently holds 1.3 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Allarity Therapeutics has a current ratio of 0.86, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Allarity Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (11.9 M) with loss before overhead, payroll, taxes, and interest of (36.35 M). | |
| Allarity Therapeutics currently holds about 7.73 M in cash with (12.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75. | |
| Roughly 12.0% of Allarity Therapeutics shares are held by company insiders | |
| Latest headline from globenewswire.com: Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements |
Allarity Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Allarity Stock often depends not only on the future outlook of the current and potential Allarity Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Allarity Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 3317.91 | |
| Cash And Short Term Investments | 166 K |
Allarity Therapeutics Technical Analysis
Allarity Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Allarity Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Allarity Therapeutics. In general, you should focus on analyzing Allarity Stock price patterns and their correlations with different microeconomic environments and drivers.
Allarity Therapeutics Predictive Forecast Models
Allarity Therapeutics' time-series forecasting models is one of many Allarity Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Allarity Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Allarity Therapeutics
Checking the ongoing alerts about Allarity Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Allarity Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Allarity Therapeutics generated a negative expected return over the last 90 days | |
| Allarity Therapeutics has high historical volatility and very poor performance | |
| Allarity Therapeutics may become a speculative penny stock | |
| Allarity Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Allarity Therapeutics currently holds 1.3 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Allarity Therapeutics has a current ratio of 0.86, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Allarity Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (11.9 M) with loss before overhead, payroll, taxes, and interest of (36.35 M). | |
| Allarity Therapeutics currently holds about 7.73 M in cash with (12.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75. | |
| Roughly 12.0% of Allarity Therapeutics shares are held by company insiders | |
| Latest headline from globenewswire.com: Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements |
Additional Tools for Allarity Stock Analysis
When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.